Four prominent health centers joined the Pediatric Brain Tumor Consortium, including Dana-Farber Cancer Institute, The Hospital for Sick Children, University of Florida, and Nationwide Children’s Hospital. Sponsored by the National Cancer Institute (NCI), the multidisciplinary collaborative research endeavor commits to intense investigation into tumor biology as well as new drugs and treatments for children with central nervous system tumors. Formed back in 1999, the Consortium’s members collaborate and transfer knowledge to facilitate clinical trials investigating new potential treatments. The Consortium just doesn’t sign up institutions: selection is the result of a competitive process involving a number of factors from expertise and translational research capability to clinical research infrastructure.
Now in its 20th year, the PBTC comprises now 15 academic centers and children’s hospitals located across the United States which are competitively selected based on their scientific excellence and clinical expertise in pediatric brain tumors. The existing participating sites include: Children’s Hospital Los Angeles, Lucile Packard Children’s Hospital Stanford, Children’s Hospital Colorado, Children’s National Medical Center Washington, Children’s Hospital of Atlanta, Ann & Robert H. Lurie Children’s Hospital of Chicago, NIH-Pediatric Oncology Branch, Memorial Sloan Kettering Cancer Center, Cincinnati Children’s Hospital Medical Center, Children’s Hospital of Pittsburgh, St. Jude Children’s Research Hospital, Texas Children’s Cancer Center.